Plasmodium Falciparum Clinical Trial
Official title:
A Phase IIb Randomized, Double-blind, Controlled Study of the Safety, Immunogenicity and Proof-of-concept of RTS,S/AS02A, and RTS,S/AS01B, Two Candidate Malaria Vaccines in Malaria-experienced Adults Living in Western Kenya.
The candidate malaria vaccine RTS,S/AS02A developed by GSK Biologicals demonstrated 30% efficacy against clinical episodes of malaria and approximately 58% efficacy against severe malaria disease. As a potential improvement to RTS,S/AS02A, another candidate vaccine RTS,S/AS01B is being developed in parallel in collaboration with the Walter Reed Army Institute of Research (WRAIR). This study will be the first administration of the RTS,S/AS01B vaccine to the African adults to establish safety and immunogenicity in this population. Preliminary indication of vaccine efficacy with this adjuvant will be established by monitoring the time to the first infection with Plasmodium falciparum.
The study comprises of 3 groups and the participating subjects will be randomly allocated to one of the three groups. The first group will receive RTS,S/AS01B, the second group will receive RTS,S/AS02A and the third group will receive rabies vaccine. Immunization will be given by IM injection on 0, 1, 2 month schedule. Infants will be followed up daily for 7 days for solicited symptoms and 30 days for unsolicited symptoms after each vaccine dose. Serious adverse events will be recorded throughout the study period. A week prior to Dose 3, subjects will be treated with a licenced anti-malarial drug. Starting from two weeks after Dose 3, the subjects will be monitored for a 14-week duration for detection of malaria infection. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01935882 -
Low Dose Primaquine for Clearance of Gametocytes
|
Phase 2/Phase 3 | |
Completed |
NCT01728701 -
Controlled Human Malaria Infection (CHMI) After Immunization With Cryopreserved Plasmodium Falciparum Sporozoites Under Chloroquine Prophylaxis
|
Phase 1 | |
Completed |
NCT01775592 -
Plasmodium Falciparum Artemisinin Resistance Vietnam
|
Phase 4 | |
Completed |
NCT00914225 -
Effect of Bednets and a Water Purification Device on HIV Disease Progression Among ART naïve Patients in Kenya
|
N/A | |
Completed |
NCT02895568 -
Prevalence Survey of Plasmodium Falciparum Antimalarial Drug Resistance Markers
|
||
Completed |
NCT02259426 -
Dihydroartemisinin-piperaquine With Low Dose Primaquine to Reduce Malaria Transmission
|
Phase 3 | |
Completed |
NCT01465048 -
Optimisation of Controlled Human Malaria Infection Using Sporozoites Administered by Needle and Syringe
|
N/A | |
Completed |
NCT00392015 -
NMRC-M3V-Ad-PfCA Vaccine - Clinical Trial 1
|
Phase 1/Phase 2 | |
Completed |
NCT04661579 -
RTS,S/AS01E Hypo-immuno-responsiveness Study
|
Phase 2 | |
Recruiting |
NCT05400746 -
A Study of the Plasmodium Falciparum Malaria Vaccine Candidate Pfs48/45 in Matrix-M Adjuvant in the UK
|
Early Phase 1 | |
Completed |
NCT03138096 -
Safety and Protective Efficacy of Pb(PfCS@UIS4)
|
Phase 1/Phase 2 | |
Completed |
NCT03452475 -
Comparison of Arterolane-piperaquine Versus Arterolane-piperaquine+Mefloquine Versus Artemether-lumefantrine in Kenyan Children
|
Phase 3 | |
Completed |
NCT00295581 -
PpPfs25/ISA51 and ScPvs25/ISA51 Vaccines for Malaria
|
Phase 1 | |
Withdrawn |
NCT04203186 -
A Clinical Trial to Evaluate Plasmodium Falciparum 7G8 and NF54 Challenge Strains (PfSPZ) in a Head-to-head Comparative Study - (ECG-CHMI)
|
N/A | |
Completed |
NCT02418962 -
Safety and Immunogenicity of Direct Venous Inoculation of a Radiation-attenuated PfSPZ Vaccine in Equatoguinean Adults
|
Phase 1 | |
Completed |
NCT01160562 -
Pilot Study to Estimate the Burden and Distribution of Plasmodium Falciparum Malaria in Kalifabougou, Mali in Preparation for a Prospective Cohort Study of Naturally-Acquired Malaria Immunity
|
||
Terminated |
NCT04445103 -
The Malaria Heart Disease Study
|
||
Completed |
NCT03132402 -
ELISA Validation of Hypersensitive Rapid Diagnostic Test Results for Detection of P. Falciparum
|
||
Completed |
NCT03172221 -
Clinical Performance of the HRP2 HS-RDT for Malaria Diagnosis in Pregnant Women
|
||
Not yet recruiting |
NCT03219281 -
Prevalence Survey of Antimalarial Drug Resistance Markers at Sites in India
|
N/A |